WO2007093184A3 - Treatment of mmp-mediated dermatological diseases with pemirolast - Google Patents

Treatment of mmp-mediated dermatological diseases with pemirolast Download PDF

Info

Publication number
WO2007093184A3
WO2007093184A3 PCT/DK2007/050020 DK2007050020W WO2007093184A3 WO 2007093184 A3 WO2007093184 A3 WO 2007093184A3 DK 2007050020 W DK2007050020 W DK 2007050020W WO 2007093184 A3 WO2007093184 A3 WO 2007093184A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pemirolast
mmp
dermatological diseases
mediated
Prior art date
Application number
PCT/DK2007/050020
Other languages
French (fr)
Other versions
WO2007093184B1 (en
WO2007093184A2 (en
Inventor
Morten Sloth Weidner
Original Assignee
Astion Pharma As
Astion Inflammation Aps
Morten Sloth Weidner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Pharma As, Astion Inflammation Aps, Morten Sloth Weidner filed Critical Astion Pharma As
Publication of WO2007093184A2 publication Critical patent/WO2007093184A2/en
Publication of WO2007093184A3 publication Critical patent/WO2007093184A3/en
Publication of WO2007093184B1 publication Critical patent/WO2007093184B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Abstract

The invention relates to compounds for the treatment of dermatological diseases where inflammation, matrix metalloproteinases (MMPs) and peroxisome proliferator- activated receptors (PPARs) play a role in mediating the disease, such as the 5 treatment of acne with Pemirolast or a closely related compound thereof.
PCT/DK2007/050020 2006-02-13 2007-02-13 Treatment of mmp-mediated dermatological diseases with pemirolast WO2007093184A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77252706P 2006-02-13 2006-02-13
EP06002867.7 2006-02-13
US60/772,527 2006-02-13
EP06002867 2006-02-13

Publications (3)

Publication Number Publication Date
WO2007093184A2 WO2007093184A2 (en) 2007-08-23
WO2007093184A3 true WO2007093184A3 (en) 2007-10-25
WO2007093184B1 WO2007093184B1 (en) 2007-11-29

Family

ID=37907280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2007/050020 WO2007093184A2 (en) 2006-02-13 2007-02-13 Treatment of mmp-mediated dermatological diseases with pemirolast

Country Status (1)

Country Link
WO (1) WO2007093184A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457932A (en) * 1983-07-22 1984-07-03 Bristol-Myers Company Anti-ulcer agents
WO1993016076A1 (en) * 1992-02-13 1993-08-19 Chinoin Gyógyszer- És Vegyészeti Termékek Gyára Rt. 3-(1h^_-tetrazol-5-yl)-4h^_-pyrido[1,2-a^_]pyrimidine-4-ones, pharmaceutical compositions containing the same and the preparation thereof
US5527802A (en) * 1992-10-01 1996-06-18 Bristol-Myers Squibb Company New uses of 3-tetrazolo -5,6,7,8- substituted-pyrido (1,2-a) pyrimidin-4-ones
JP2004345984A (en) * 2003-05-21 2004-12-09 Mitsubishi Pharma Corp Agent for preventing and reducing sensitive reaction caused by administration of anti-cancer agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457932A (en) * 1983-07-22 1984-07-03 Bristol-Myers Company Anti-ulcer agents
WO1993016076A1 (en) * 1992-02-13 1993-08-19 Chinoin Gyógyszer- És Vegyészeti Termékek Gyára Rt. 3-(1h^_-tetrazol-5-yl)-4h^_-pyrido[1,2-a^_]pyrimidine-4-ones, pharmaceutical compositions containing the same and the preparation thereof
US5527802A (en) * 1992-10-01 1996-06-18 Bristol-Myers Squibb Company New uses of 3-tetrazolo -5,6,7,8- substituted-pyrido (1,2-a) pyrimidin-4-ones
JP2004345984A (en) * 2003-05-21 2004-12-09 Mitsubishi Pharma Corp Agent for preventing and reducing sensitive reaction caused by administration of anti-cancer agent

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
CROSSWELL A R ET AL: "COMPARATIVE HEALING EFFECTS OF RANITIDINE AND A NON-ANTISECRETORY CYTOPROTECTIVE AGENT BMY-26517-31 IN A RAT CHRONIC ULCER MODEL", GASTROENTEROLOGY, vol. 90, no. 5 PART 2, 1986, & ABSTRACTS OF PAPERS SUBMITTED TO THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION FOR THE 87TH ANNUAL ME, pages 1383, XP008080170, ISSN: 0016-5085 *
DATABASE WPI Week 200506, Derwent World Patents Index; AN 2005-050876, XP002446542 *
FUJIMIYA HIROSHI ET AL: "An antiallergic drug, pemirolast potassium, inhibits inositol 1,4,5-trisphosphate production and Ca-2+ mobilization in antigen-stimulated rat basophilic leukemia (RBL-2H3) cells", JAPANESE JOURNAL OF ALLERGOLOGY, vol. 43, no. 2, 1994, pages 142 - 151, XP008082344, ISSN: 0021-4884 *
GOUS P ET AL: "A COMPARISON OF THE SAFETY AND EFFICACY OF 0.1% PEMIROLAST POTASSIUM OPHTHALMIC SOLUTION DOSED TWICE DAILY ( BID ) VERSUS FOUR TIMES DAILY ( QID ) IN PATIENTS WITH SEASONAL ALLERGIC CONJUNCTIVITIS ( SAC )", ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2003, 2003, & ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY; FORT LAUDERDALE, FL, USA; MAY 04-08, 2003, pages Abstract No. 3732, XP008066516 *
KOBAYASHI K ET AL: "EFFECTS OF QUINOTOLAST, A NEW ORALLY ACTIVE ANTIALLERGIC DRUG, ON EXPERIMENTAL ALLERGIC MODELS", JAPANESE JOURNAL OF PHARMACOLOGY, THE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, JP, vol. 63, 1993, pages 73 - 81, XP000925853, ISSN: 0021-5198 *
LEMA I ET AL: "Inflammatory Molecules in the Tears of Patients with Keratoconus", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 112, no. 4, April 2005 (2005-04-01), pages 654 - 659, XP004829804, ISSN: 0161-6420 *
LEONARDI A A ET AL: "Differential expression of matrix metalloproteinases in vernal keratoconjunctivitis, allergic asthma and nasal polyps", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 46, no. Suppl S, 2005, pages 936, XP008066619, ISSN: 0146-0404 *
LEONARDI A ET AL: "Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 44, no. 7, 1 July 2003 (2003-07-01), pages 3052 - 3058, XP008066620, ISSN: 0146-0404 *
MIYAKE-KASHIMA, MINORI ET AL: "Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis", JAPANESE JOURNAL OF OPHTHALMOLOGY , 48(6), 587-590 CODEN: JJOPA7; ISSN: 0021-5155, 2004, XP008066557 *
NISHIZAWA Y ET AL: "EFFECTS OF ANTIALLERGIC DRUGS ON THE PROLIFERATION OF ESTROGEN- SENSITIVE MOUSE LEYDIG CELL LINE", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 16, no. 3A, 1996, pages 1241 - 1246, XP001050577, ISSN: 0250-7005 *
SUNDARRAJ C V ET AL: "Managing symptoms of allergy and dry eye in patients with keratoconus", IOVS, vol. 46, no. Suppl. S, 2005, & ANNUAL MEETING OF THE ASSOCIATION-FOR-RESEARCH-IN-VISION-AND-OPHTHALM OLOGY; FT LAUDERDALE, FL, USA; MAY 01 -05, 2005, pages 941, XP008066530, ISSN: 0146-0404 *
YAHATA, HIDEAKI ET AL: "Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer", INTERNATIONAL JOURNAL OF CANCER , 118(10), 2636-2638 CODEN: IJCNAW; ISSN: 0020-7136, 2006, XP008082338 *
YANAGIHARA Y ET AL: "Immunopharmacological studies on TBX, a new antiallergic drug. (4) Effects on type II to IV allergic reactions and immunological functions in animal models", JAPANESE JOURNAL OF PHARMACOLOGY 1989 JAPAN, vol. 51, no. 1, 1989, pages 93 - 100, XP008066536, ISSN: 0021-5198 *
YOSHINUMA M: "Preventive mechanisms and effects of pemirolast potassium on restenosis after percutaneous transluminal coronary angioplasty: Serial coronary angiography and intravascular ultrasound studies", JOURNAL OF CARDIOLOGY 1999 JAPAN, vol. 33, no. 2, 1999, pages 81 - 88, XP008082347, ISSN: 0914-5087 *

Also Published As

Publication number Publication date
WO2007093184B1 (en) 2007-11-29
WO2007093184A2 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
WO2006094209A3 (en) N-benzimidazolylalkyl-substituted amide sirtuin modulators
WO2007010281A3 (en) Use of thiazole derivatives and analogues in disorders caused by free fatty acids
WO2006084176A3 (en) Compounds and compositions as ppar modulators
WO2008156869A3 (en) Sirtuin modulating thiazolopyridine compounds
WO2008033460A3 (en) Treating pain, diabetes, and lipid metabolism disorders
WO2011012746A3 (en) Apaf-1 inhibitor compounds
ATE546142T1 (en) SALTS AND POLYMORPHOS OF AN EFFECTIVE ANTIDIABETIC COMPOUND
MY149316A (en) Sirtuin modulating imidazohiazole compounds
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
DK2150530T3 (en) Substituted sulfonamide derivatives
MX2011006555A (en) Thiazolopyridine sirtuin modulating compounds.
WO2006108424A3 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
WO2009134973A8 (en) Quinolines and related analogs as sirtuin modulators
WO2010037127A8 (en) Chromenone analogs as sirtuin modulators
EP1726580A4 (en) Aminophenylpropanoic acid derivative
MX2010004965A (en) Amide derivatives as sirtuin modulators.
UY32032A (en) "2- [1-SUBSTITUTED-1H-PIRAZOLO [3,4-D] PIRIMIDIN-4-IL] (IO, OXI OR AMINO) -N- (HETEROARIL) ALCANAMIDS"
CL2008000594A1 (en) USE OF COMPOUNDS DERIVED FROM HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND OTHER ACTIVE AGENTS; AND ITS USE TO TREAT DIABETES, CORONARY ARTERIAL DISEASE BETWEEN OTHER DISEASES.
WO2006094210A3 (en) Tetrahydroquinoxalinone sirtuin modulators
WO2007056366A3 (en) Compounds and compositions as ppar modulators
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
MX2010005186A (en) Solubilized thiazolopyridines.
WO2007017126A3 (en) POLYMORPH OF N-PIPERIDINYL-5- (4-CHLOROPHENYL) -1- (2, 4-DICHLOROPHENYL) -4, 5-DIHYDRO-lH-PYRAZOLE- 3 -CARBOXAMIDE AND ITS USE AS A CAMNABINOID RECEPTOR MODULATOR
WO2006108682A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07711308

Country of ref document: EP

Kind code of ref document: A2